A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis

IBD98-M is a delayed-release formulation of mesalamine (mesalazine) and SH with a potential therapeutic role in ulcerative colitis (UC). A total of 51 patients with a modified Ulcerative Colitis Disease Activity Index (UCDAI) score of ≥4 and ≤10, and a modified UCDAI endoscopy subscore ≥1 were rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorino, Gionata, Sturniolo, Giacomo Carlo, Bossa, Fabrizio, Cassinotti, Andrea, Di Sabatino, Antonio, Giuffrida, Paolo, Danese, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627752/
https://www.ncbi.nlm.nih.gov/pubmed/31151306
http://dx.doi.org/10.3390/cells8060523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627752/
https://www.ncbi.nlm.nih.gov/pubmed/31151306
http://dx.doi.org/10.3390/cells8060523

Ejemplares similares